1. Home
  2. SLRC vs REPL Comparison

SLRC vs REPL Comparison

Compare SLRC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLR Investment Corp.

SLRC

SLR Investment Corp.

HOLD

Current Price

$14.95

Market Cap

818.3M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$7.97

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRC
REPL
Founded
2007
2015
Country
US
US
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
818.3M
781.3M
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
SLRC
REPL
Price
$14.95
$7.97
Analyst Decision
Hold
Buy
Analyst Count
7
9
Target Price
$16.04
$11.13
AVG Volume (30 Days)
234.6K
1.1M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
10.96%
N/A
EPS Growth
25.71
5.25
EPS
1.24
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.64
$2.68
52 Week High
$17.94
$14.80

Technical Indicators

Market Signals
Indicator
SLRC
REPL
Relative Strength Index (RSI) 44.04 53.17
Support Level $14.76 $7.43
Resistance Level $15.21 $8.41
Average True Range (ATR) 0.30 0.53
MACD 0.00 0.13
Stochastic Oscillator 48.13 77.61

Price Performance

Historical Comparison
SLRC
REPL

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: